Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Gilead Investors' Nightmare Scenario

This episode of The Motley Fool's Market Checkup is dedicated to the world's largest pure-play biotech stock, Gilead Sciences  (NASDAQ: GILD  ) . Market Checkup gives a full examination of Gilead's second-quarter results, takes a closer look at the company's current product portfolio, and analyzes the future drugs that have investors excited about the stock's future.

In this video, health-care analysts David Williamson and Max Macaluso drill down on Gilead's strong drug development pipeline. Watch and find out what makes pending hepatitis-C drug candidate sofosbuvir both so exciting and potentially dangerous for Gilead investors.

Sofosbuvir is a nucleotide inhibitor, and the only member of its hep-C drug class to make it through clinical trials without major safety issues. However, if a problem reared its head once the drug were on sale, it could have a devastating effect on Gilead shares. Watch David and Max discuss this "what-if" scenario in the video.

It's no secret that biotech stocks like Gilead have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.

Read/Post Comments (2) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 14, 2013, at 3:15 PM, boczernyk wrote:

    look into sofosbuvir & ECG irregular heartbeat exclusions. screening 4 the GILD hepC trials included an ECG. Also will say that GILD enrollees were best/ healthiest vs other trial sponsors. I ultimately got into ABBV non-cirrhotic naive, excluded from GILD?

  • Report this Comment On September 16, 2013, at 2:02 PM, RMax304823 wrote:

    Is GILD deliberately excluding subjects with irregular heartbeats? If so, it would be interesting to know why. Do they already have evidence that the hepC drug doesn't work with them, or that they have evidence that it's dangerous. If neither of these conditions prevail, then why are the patients being excluded?

    "Don't keep something secret if you have nothing to hide" is nonsense in politics, but it's the backbone of scientific research.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2637776, ~/Articles/ArticleHandler.aspx, 9/27/2016 11:58:52 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 hours ago Sponsored by:
DOW 18,228.30 133.47 0.74%
S&P 500 2,159.93 13.83 0.64%
NASD 5,305.71 48.22 0.92%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/27/2016 4:00 PM
GILD $79.25 Down -1.37 -1.70%
Gilead Sciences CAPS Rating: *****
BMY $55.74 Up +0.26 +0.47%
Bristol-Myers Squi… CAPS Rating: ****
VRTX $89.12 Up +0.83 +0.94%
Vertex Pharmaceuti… CAPS Rating: ****